Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study

BMC Nephrology

Table 2 Quality of life, depression, daytime sleepiness, sleep quality and RLS symptom’s severity data divided in three groups divided in three groups according to the assigned intervention

Variables	Exercise group	Dopamine agonists group	Placebo group
Sleep Diary
Baseline	7.69±5.51	10.28±2.87	8.42±5.09
6-m post	7.30±4.13	5.85±3.71†	8.85±4.09
Δ Change	−0.71±3.22	- 4.42±3.10#¶	0.42±2.7
95% CI of Δ change	−2.49 to 1.07	−7.28 to −1.56	2.91 to −2.07
Epworth Sleepiness Scale
Baseline	5.15±2.54	7.85±5.24	8.71±5.37
6-m post	5.15±2.47	5.42±1.98	8.42±4.92
Δ Change	−0.35±2.73	−2.42±5.38	- 0.28±4.19
95% CI of Δ change	−1.85 to 1.15	−7.39 to 2.55	−4.15 to 3.59
Zung Depression Scale
Baseline	43.45±8.06	46.85±13.49	37.85±12.15
6-m post	35.84±6.38†#	39.42±4.35	43.71±11.17†¶
Δ Change	−8.28±7.91#	−7.42±10.34#	5.85±6.41
95% CI of Δ change	−12.60 to −3.91	−16.96 to 2.12	11.70 to −0.07
IRLS score
Baseline	25.14±9.09	24.14±5.55	19.71±7.49
6-m post	13.42±11.28†	11.57±7.84†	18.57±10.65
Δ Change	−13.12±8.59#	- 12.57±5.31#	- 1.14±8.43
95% CI of Δ change	−17.87 to −8.37	−17.47 to −7.67	−8.93 to 6.65
SF-36 MCS score
Baseline	61.1±22.0	39.1±23.8	68.1±19.1
6-m post	70.4±18.7	63.0±17.0†	65.0±21.9
Δ Change	9.3±26.7	23.8±14.1	3.1±9.8
95% CI of Δ change	24.1 to 5.4	36.9 to 10.7	5.9 to −12.2
SF-36 PCS score
Baseline	64.9±18.6	48.7±21.0	64.4±22.5
6-m post	76.4±15.6†	68.8±19.2†	70.5±26.5
Δ Change	11.5±18.4	20.1±6.0	6.1±5.7
95% CI of Δ change	21.7 to 1.2	25.7 to 14.5	20.2 to −7.9

All data are mean ± SD. Abbreviations: IRLS International restless legs syndrome severity scale, SF-36 Self reported quality of life questionnaire, MCS Mental component summary, PCS Physical component summary.
#Significantly different than placebo group.
¶Significantly different than exercise group.
†Significantly different from the respective baseline value.